Zoning Changes Kills Sale of Bristol-Myers Squibb's Connecticut Campus

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-bristol-myers-squibb.jpg" NAME"Zoning Changes Kills Sale of Bristol-Myers Squibb's Connecticut Campus" ALT"Zoning Changes Kills Sale of Bristol-Myers Squibb's Connecticut Campus"February 21, 2017By Alex Keown, BioSpace.com... Source: BioSpace

Continue ReadingZoning Changes Kills Sale of Bristol-Myers Squibb's Connecticut Campus

Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-sarepta-ed-kaye.jpg" NAME"Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million" ALT"Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for…

Continue ReadingSarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million

Here???s Where Jobs in Shrinking Life Sciences Marketing Departments Are Headed

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-scorr- cliff-echols.jpg" NAME"Heres Where Jobs in Shrinking Life Sciences Marketing Departments Are Headed" ALT"Heres Where Jobs in Shrinking Life Sciences Marketing Departments Are Headed"February 20, 2017By Cliff Echols, BioSpace.com…

Continue ReadingHere???s Where Jobs in Shrinking Life Sciences Marketing Departments Are Headed

Norwegian Biotech Upstart Has Become a Potential Takeover Target

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks3.jpg" NAME"Norwegian Biotech Upstart Has Become a Potential Takeover Target" ALT"Norwegian Biotech Upstart Has Become a Potential Takeover Target"February 20, 2017By Alex Keown, BioSpace.com Breaking News Staff... Source: BioSpace

Continue ReadingNorwegian Biotech Upstart Has Become a Potential Takeover Target